As Recalls Multiply, EU Agency Studies How To Rid Chinese Firm’s Valsartan API Of Probable Carcinogen
Executive Summary
European authorities are examining how a manufacturing process change six years ago may have introduced a probable carcinogen into Zhejiang Huahai’s valsartan API that was only recently detected. They hope to learn how the firm could reduce or eliminate the impurity.
You may also be interested in...
USP Nitrosamine Impurities Chapter Reflects Coordination With EU As Well US Agencies
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.
USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.
Enforcing A Belated Chemistry Lesson – The Nitrosamines In Sartans Saga
How authorities plan to root out the carcinogenic impurities and what it means for other classes of medicines.